1[1]Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System[J]. J Infect Dis. 1993,167:1247-1251
2[2]Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital[J]. J Infect. 1996,33:23-32
3[3]Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance[J]. Am J Med, 1996,100:617-623
4[4]Pfaller MA, Diekema DJ, Jones RN, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000[J]. J Clin Microbiol. 2002,40:852-856
5[5]Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program[J].. J Clin Microbiol, 2001,39:3254-3259
6[6]Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole[J]. Expert Opin Investig Drugs, 2002,11:409-429
7[7]Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent[J]. Clin Infect Dis, 2003,36:630-637
8[8]Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa[J]. Antimicrob Agents Chemother, 1999,43:169-171
9[9]Yildiran ST, Fothergill AW, Sutton DA, et al. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592)[J]. Mycoses, 2002,45:378-383
10[10]Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000[J]. Antimicrob Agents Chemother, 2002,46:1032-1037
